LLY vs. PLTR: Eli Lilly vs. Palantir Stock Comparison

Company Profile

Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Palantir (PLTR) belongs to Information Technology (Software & Services) — their GICS classifications point to very different parts of the market.

Eli Lilly (LLY) has more than two decades of public-market history since June 1, 1972, whereas Palantir (PLTR) listed on September 30, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Palantir (PLTR) has an aggressive beta of 1.63, indicating higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.40 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Eli Lilly (LLY) at 86.02% and Palantir (PLTR) at 40.91% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Eli Lilly (LLY) at 31.90% and Palantir (PLTR) at 50.34% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Eli Lilly (LLY) at 53.66% and Palantir (PLTR) at 46.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Palantir (PLTR) at 56.18% clears its industry range for revenue growth, far stronger top-line momentum than Eli Lilly (LLY) at 44.70%, which is closer to a typical peer reading.

Both companies show strong earnings momentum, but Palantir (PLTR) at 231.06% is the standout with EPS growth above its industry range; Eli Lilly (LLY) at 95.99% also sits in the top quartile.

Growth Metrics

Financial Strength

Palantir (PLTR) at 7.10 carries current ratio above its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Palantir (PLTR) at 0.02 keeps leverage in the lower quartile, while Eli Lilly (LLY) at 1.23 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Palantir (PLTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

Palantir (PLTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Eli Lilly (LLY) at 43.95 and Palantir (PLTR) at 112.94 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

Eli Lilly (LLY) at 13.95 prices around its industry’s typical P/S ratio, while Palantir (PLTR) at 53.02 clears its benchmark range — PLTR looks notably rich on sales.

Measured against book value, both Eli Lilly (LLY) at 29.96 and Palantir (PLTR) at 34.41 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics